A 62-year-old man presents to the clinic to discuss pancreatic cancer screening. He has no current symptoms of abdominal pain, jaundice, or weight loss. Vital signs are within normal limits, and physical examination is unremarkable. His father and paternal uncle both died of pancreatic adenocarcinoma, prompting his enrollment in a high-risk familial surveillance registry. Epidemiological data indicates that the prevalence of early-stage pancreatic adenocarcinoma in this specific surveillance cohort is .
As part of a new clinical protocol, the patient's blood is tested using a novel multi-target serum biomarker panel. The assay has a validated sensitivity of and a specificity of for detecting early-stage disease.
The patient's biomarker panel returns a positive result.
Based on the provided test characteristics and cohort prevalence, what is the post-test probability (in percent) that this patient actually has early-stage pancreatic adenocarcinoma?
Cevap: 50 %
Cevap
Using a hypothetical cohort of patients:
- Number of patients with disease:
- Number of patients without disease:
Next, calculate the number of positive test results in each group:
- True positives (TP) =
- False positives (FP) =
The total number of positive test results is .
PPV = (or ).
Therefore, the probability that the patient has early-stage pancreatic adenocarcinoma is .